# Glp1 Obesity Agent Nv Profile

> Look up drug-specific nausea and vomiting rates across the full generation of GLP-1-based obesity agents — semaglutide 2.4 mg, semaglutide 7.2 mg, CagriSema, tirzepatide, retatrutide, survodutide, oral semaglutide 25/50 mg, and orforglipron — to counsel patients before initiation or to decide which agent to switch to when tolerability is the deciding factor. Use when a clinician asks "how much nausea should I expect on Wegovy vs Zepbound", "retatrutide vs semaglutide tolerability", "CagriSema side effect profile", "orforglipron vs oral semaglutide", or when a patient needs pre-initiation counselling numbers for a specific obesity GLP-1-based agent. Grounded in Alhazmi & le Roux 2026 (Front Endocrinol) with the original pivotal trial sources.

- Skill: `dromlakhani/glp1-obesity-agent-nv-profile` (Agent Skill)
- Install (CLI): `npx skillmds@latest add dromlakhani/glp1-obesity-agent-nv-profile`
- Raw SKILL.md: https://api.skillmd.com/api/skills/dromlakhani/glp1-obesity-agent-nv-profile/raw
- Safety review: pending (external: skill-scanner PASS, skillspector PASS)
- Works with: Claude Code, Claude.ai, OpenAI Codex
- Category: AI & ML
- Author: dromlakhani (https://skillmd.com/u/dromlakhani)
- Updated: 2026-09-08
- Page: https://skillmd.com/skills/dromlakhani/glp1-obesity-agent-nv-profile

---


# GLP-1 Obesity Agent — Nausea & Vomiting Profile

## Purpose

Give a clinician a single reference with:
1. **Drug-specific nausea and vomiting rates** from pivotal phase 3 trials.
2. **Weight loss at the highest studied dose** to set efficacy expectations.
3. **Mechanism class** so tolerability patterns can be anticipated.
4. **Counselling headline** to use with patients before initiation.

## When to Use

- Pre-initiation counselling: "what should I expect in terms of side effects on this drug?"
- Choosing between two agents when tolerability is the deciding factor.
- Deciding which agent to **switch to** after intolerance of the current one (use together with `glp1-dose-escalation-troubleshooter`).

## Injectable Obesity Agents

| Agent | Class | Dose / Frequency | Peak weight loss | Nausea | Vomiting |
|---|---|---|---|---|---|
| **Semaglutide 2.4 mg** (Wegovy / Noveltreat) | GLP-1 RA | 2.4 mg once-weekly SC | ~ −16.0% at 68 wks | ~ 58% | ~ 27% |
| **Semaglutide 7.2 mg** | GLP-1 RA (higher-dose) | 7.2 mg once-weekly SC | −18.7 to −20.7% at 72 wks | 43.7% | 24.8% |
| **CagriSema 2.4 mg** | Amylin analogue (cagrilintide) + GLP-1 RA | Once-weekly SC | ~ −20% at 68 wks | ~ 55% | ~ 24.7% |
| **Tirzepatide 15 mg** (Mounjaro / Zepbound) | Dual GIP / GLP-1 RA | 15 mg once-weekly SC | ~ −21% at 72 wks | 30–33% | 10–12% |
| **Retatrutide 12 mg** | Triple GIP / GLP-1 / glucagon RA | 12 mg once-weekly SC | ~ −29% at 68 wks | Up to 43% | Up to 20.9% |
| **Survodutide 4.8 mg** | Dual GLP-1 / glucagon RA | 4.8 mg once-weekly SC | ~ −15% at 46 wks | ~ 56% | ~ 27% |

## Oral Obesity Agents

| Agent | Class | Dose / Routine | Peak weight loss | Nausea | Vomiting |
|---|---|---|---|---|---|
| **Oral semaglutide 25 mg** | Peptide GLP-1 RA + SNAC | Daily, fasting, strict 30-min wait | ~ −13.6% at week 64 | ~ 47% | ~ 31% |
| **Oral semaglutide 50 mg** | Peptide GLP-1 RA + SNAC (higher exposure) | Same as 25 mg | ~ −15.1% at week 68 | ~ 52% | ~ 24% |
| **Orforglipron 36 mg** | Small-molecule GLP-1 RA (non-peptide) | Daily, no fasting | ~ −11.2% at week 36 (sustained to week 72) | ~ 33.7% | ~ 24% |

## Pattern Rules — How to Use These Numbers

1. **Higher exposure → more nausea and vomiting** within the same molecule (semaglutide 50 mg > 25 mg; semaglutide 7.2 mg > 2.4 mg).
2. **GIP addition modestly improves tolerability vs GLP-1 alone** — tirzepatide has the **lowest vomiting** of any high-efficacy injectable (~10–12%).
3. **Glucagon receptor addition re-introduces nausea/vomiting** — survodutide (dual) and retatrutide (triple) have GLP-1-like GI profiles despite GIP in retatrutide.
4. **Amylin addition (CagriSema)** adds weight loss but **increases** nausea/vomiting compared with semaglutide 2.4 mg alone (central satiety amplification).
5. **Oral route does not spare the patient** — variable plasma concentrations with oral semaglutide can cause **more** GI AEs than SC; orforglipron has the lowest N/V among orals.
6. **Weight loss and GI AE intensity are independent** — more nausea ≠ more weight loss. Use tolerability, not symptom severity, to guide escalation.

## Counselling Headlines

- **"About half of patients feel nauseated during titration. Most settle within 2–3 weeks of each new dose. The dose we end up at is the maximum you tolerate — not a number on the label."**
- If choosing **tirzepatide**: "lowest vomiting rate of the high-efficacy injectables — about 1 in 10."
- If choosing **semaglutide 2.4 mg**: "about 1 in 4 will vomit; most are mild–moderate and settle with slower titration."
- If choosing **retatrutide**: "largest weight loss but more nausea — plan for a slow escalation and behavioural measures up front."
- If choosing **oral semaglutide 50 mg**: "needs fasting + 30-min wait; about half will have nausea. Skip a dose → retake the next day; do not double up."

## Cross-References

- Dose-titration decisions (grade nausea, extend/hold/step-back/switch) → `glp1-dose-escalation-troubleshooter`
- Symptom-specific dietary advice → `glp1-gi-ae-symptom-advisor`
- Antiemetics / antidiarrhoeals / laxatives rescue → `glp1-gi-ae-pharmacological-rescue`
- Pre-initiation patient counselling → `glp1-gi-ae-patient-education`
- Candidacy in special populations (elderly, EDs, GI disease) → `glp1-candidacy-myths-checker`

## Source

Alhazmi A, le Roux CW. Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies. *Front Endocrinol* 2026;17:1788698. Tables 1 & 2 (pivotal trial sources: STEP 1, STEP UP, OASIS, STEP trial programme, SURPASS/SURMOUNT, triple-agonist phase 2/3, survodutide phase 2, CagriSema phase 3, orforglipron OASIS/ATTAIN).